US 12,173,081 B2
CD19/CD38 multispecific antibodies
Leonard Presta, San Francisco, CA (US); Paul Tumeh, San Francisco, CA (US); and Nils Lonberg, Woodside, CA (US)
Assigned to Biograph 55, Inc., San Francisco, CA (US)
Filed by Biograph 55, Inc., San Francisco, CA (US)
Filed on Mar. 21, 2024, as Appl. No. 18/612,854.
Claims priority of provisional application 63/491,441, filed on Mar. 21, 2023.
Claims priority of provisional application 63/590,886, filed on Oct. 17, 2023.
Prior Publication US 2024/0317883 A1, Sep. 26, 2024
Int. Cl. C07K 16/28 (2006.01); A61P 35/00 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/2896 (2013.01) [A61P 35/00 (2018.01); C07K 16/2803 (2013.01); A61K 39/00 (2013.01); C07K 2317/31 (2013.01)] 13 Claims
 
1. A common light chain bispecific antibody comprising:
(i) an anti-CD38 heavy chain variable region, an anti-CD38 heavy chain constant region, and a first common light chain variable region, wherein:
the anti-CD38 heavy chain variable region comprises:
a heavy chain complementarity determining region 1 (HCDR1) comprising an amino acid sequence set forth in SEQ ID NO: 7,
a heavy chain complementarity determining region 2 (HCDR2) comprising an amino acid sequence set forth in SEQ ID NO: 8,
a heavy chain complementarity determining region 3 (HCDR3) comprising an amino acid sequence set forth in SEQ ID NO: 9, and
a negatively-charged amino acid at heavy chain variable region position 1 per Kabat numbering, and
the first common light chain variable region comprises:
a light chain complementarity determining region 1 (LCDR1) comprising an amino acid sequence set forth in SEQ ID NO: 13,
a light chain complementarity determining region 2 (LCDR2) comprising the amino acid sequence AAS, and
a light chain complementarity determining region 3 (LCDR3) comprising an amino acid sequence set forth in SEQ ID NO: 15; and
(ii) an anti-CD 19 heavy chain variable region, an anti-CD 19 heavy chain constant region, and a second common light chain variable region, wherein:
the anti-human-CD 19 heavy chain variable region comprises:
a heavy chain complementarity determining region 1 (HCDR1) comprising an amino acid sequence set forth in SEQ ID NO: 10,
a heavy chain complementarity determining region 2 (HCDR2) comprising an amino acid sequence set forth in SEQ ID NO: 11,
a heavy chain complementarity determining region 3 (HCDR3) comprising an amino acid sequence set forth in SEQ ID NO: 12, and
a negatively-charged amino acid at heavy chain variable region position 1 per Kabat numbering, and
the second common light chain variable region comprises:
a light chain complementarity determining region 1 (LCDR1) comprising an amino acid sequence set forth in SEQ ID NO: 13,
a light chain complementarity determining region 2 (LCDR2) comprising the amino acid sequence AAS, and
a light chain complementarity determining region 3 (LCDR3) comprising an amino acid sequence set forth in SEQ ID NO: 15,
wherein:
the anti-CD38 heavy chain constant region and the anti-CD19 heavy chain constant region each lack a C-terminal lysine residue; and
the common light chain bispecific antibody comprises an experimental isoelectric point (pI) of less than 9.0; and
the first common light chain variable region and the second common light chain variable region comprise an identical amino acid sequence.